November 13 - 16, 2018
The Convention Centre Dublin
Abstract submission deadline: Wednesday, June 20
Advance registration deadline: Friday, May 11
Scientific Committee CochairsCharles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, England (EORTC)James L. Gulley, National Cancer Institute, Bethesda, Maryland (NCI)Antoni Ribas, UCLA Medical Center, Los Angeles, California (AACR)
Organizing Committee CochairsDenis A. Lacombe, European Organisation for Research and Treatment of Cancer, Brussels, Belgium (EORTC)James H. Doroshow, National Cancer Institute, Bethesda, Maryland (NCI)José Baselga, Memorial Sloan Kettering Cancer Center, New York, New York (AACR)
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2018 Symposium brings together academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.
Building on the success and focus of previous highly acclaimed symposiums, this drug development and translational research meeting, focusing on preclinical and phase I studies, will enable delegates to have in-depth scientific discussions on the latest developments in targets and drugs.